Google Cloud adds SandboxAQ's specialized AI models for scientific research

Google Cloud has announced it is adding specialized AI models from SandboxAQ to its cloud portfolio. Enterprise customers and research organizations will get access, primarily in pharmaceuticals, materials science, and semiconductor manufacturing. The partnership expands Google Cloud's reach into niches where standard language models aren't accurate enough.

Models for real science

SandboxAQ spun out of Alphabet as an independent company in 2022. From the start, it targeted a niche the biggest AI companies avoid: problems that require a deep understanding of physics and chemistry, not just processing text about those subjects.

SandboxAQ's models are not general-purpose language systems. They are trained on specialized scientific datasets: molecular structures, crystallographic parameters, spectral data, and manufacturing metrics. Where GPT or Gemini "know" about a molecule from text descriptions, SandboxAQ's models work directly with its structure.

Key areas available through Google Cloud:

• Drug discovery — finding candidate molecules for new drugs, predicting toxicity and interactions, and screening out unpromising compounds early
• Materials science — predicting the properties of new materials and designing polymers and alloys with target characteristics
• Semiconductor manufacturing — optimizing manufacturing processes, cutting defects, and improving chip yield
• Quantum security — developing cryptographic protocols that can withstand attacks from quantum computers

Why Google Cloud wants this

Google Cloud has been steadily building an ecosystem of AI models beyond its own Gemini. Vertex AI already offers Anthropic Claude, Meta Llama, and models from other specialized providers. SandboxAQ fits the strategy of a single "AI store": an enterprise customer picks the right tool for the job, all in one interface, with no extra contracts.

For research organizations, this brings concrete practical benefits. They don't need to build separate compute infrastructure, sign separate agreements, or set up integrations with each provider individually. SandboxAQ's models will be available through standard Google Cloud tools with the usual data security and regulatory compliance guarantees — which is critical for pharmaceutical companies handling sensitive research.

The Alphabet connection is no coincidence: Alphabet remains one of SandboxAQ's key investors after the spinout. Bringing the models to Google Cloud is a logical extension of that relationship, and it also strengthens the cloud division in segments built on long-term enterprise contracts.

What changes for the industry

Biotech startups and university labs have traditionally faced a tough choice: build their own expensive compute infrastructure or live with the limits of general-purpose AI tools. Specialized models delivered through the cloud open a third path — professional-grade tools without capital spending on hardware.

In the semiconductor industry, AI-driven process optimization has already become a strategic priority. At industrial scale, raising chip yield by even a few percent translates into savings in the hundreds of millions of dollars. Cloud access puts this tool within reach not only of industry leaders but also of mid-sized manufacturers.

Drug development is another area with huge potential. The traditional path from idea to market takes a decade and costs billions of dollars. Using AI to speed up individual stages — compound screening, interaction prediction — can shorten that cycle and cut research costs.

What it means

Specialized scientific AI models are moving from research prototypes to commercial infrastructure. SandboxAQ's arrival on Google Cloud lowers the barrier to adoption, both technical and organizational. For pharmaceuticals, materials science, and semiconductors, where development cycles run for years and mistakes are expensive, this is a potential competitive advantage.

*Meta is designated an extremist organization and banned in Russia.